ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its
novel antibody drug conjugates (ADCs) have been accepted for
presentation at the American Association for Cancer Research (AACR)
Annual Meeting, which will be held in San Diego, CA from April
5-10, 2024.
“We’re excited to share compelling preclinical data supporting
the future clinical development of the next-generation ADCs in our
solid tumor portfolio, including those targeting Claudin-6 and
NaPi2b, at the AACR Annual Meeting,” said Mohamed Zaki, MD, PhD,
Chief Medical Officer of ADC Therapeutics. “We’re also looking
forward to research from independent studies that highlight the
potential of another investigational ADC, ADCT-601 targeting
AXL.”
Details of ADC Therapeutics’ poster presentations are as
follows:
Title: Preclinical development of a novel
camptothecin-based antibody-drug conjugate targeting solid tumors
expressing Claudin-6
Abstract: 3122Session Title:
Antibody-Drug ConjugatesDate and
Time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m.
PTLocation: Poster Section 21; Board number
3
Title: Preclinical development of
NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate
targeting solid tumors expressing NaPi2b Abstract:
5085Session Title: Novel Immunotherapies and
Immune ModulationDate and Time: Tuesday,
April 9, 2024; 9:00 a.m. – 12:30 p.m. PTLocation:
Poster Section 42; Board number 7
Title: Phase 1b Trial Mipasetamab Uzoptirine
(ADCT-601-102) dose escalation in patients with advanced bone and
soft tissue sarcomasAbstract: CT059Session
Title: Phase I Clinical Trials 1Date and
Time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m.
PTLocation: Poster Section 48; Board number 9
Title: Quantitative systems pharmacology
modeling of loncastuximab tesirine combined with mosunetuzumab and
glofitamab helps guide dosing for patients with
DLBCLAbstract: 875Session Title:
Application of Bioinformatics to Cancer Biology 1Date and
Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m.
PTLocation: Poster Section 36; Board number 19
Details of an independent poster presentation of an ADCT-601
preclinical study are as follows:
Title: Preclinical anti-tumorigenic evaluation
of AXL targeting antibody-drug-conjugate in an adenoid cystic
carcinoma cell line xenograft modelAbstract:
LB022Session Title: Late-Breaking Research:
ChemistryDate and Time: Sunday, April 7, 2024;
1:30 p.m. – 5:00 p.m. PTLocation: Poster Section
52; Board number 4
Details of an oral presentation of an NCI-led ADCT-701 study are
as follows:
Title: Targeting DLK1, a Notch ligand, with an
antibody-drug conjugate in adrenocortical
carcinomaAbstract: 6573Session
Type: MinisymposiumSession Title:
Molecular, Preclinical, and Clinical Endocrinology 3Date
and Time: Tuesday, April 9, 2024; 3:05 p.m.
– 3:20 p.m. PTLocation: TBA
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases you can identify
forward-looking statements by terminology such as “may”, “will”,
“should”, “would”, “expect”, “intend”, “plan”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “seem”, “seek”,
“future”, “continue”, or “appear” or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: future
success and results from the various ADCT development programs
presented at AACR, the actual ZYNLONTA® revenue for 4Q 2023, the
success of the Company’s updated corporate strategy including
operating efficiencies, capital deployment and portfolio
prioritization; the Company’s ability to achieve the decrease in
total operating expenses for 2023 and 2024, the expected cash
runway into 4Q 2025, the effectiveness of the new commercial
go-to-market strategy, competition from new technologies, and the
Company’s ability to grow ZYNLONTA® revenue in the United States;
Swedish Orphan Biovitrum AB (Sobi®) ability to successfully
commercialize ZYNLONTA® in the European Economic Area and market
acceptance, adequate reimbursement coverage, and future revenue
from the same; approval by the NMPA of the BLA for ZYNLONTA® in
China submitted by Overland ADCT BioPharma and future revenue from
the same, our strategic partners’, including Mitsubishi Tanabe
Pharma Corporation, ability to obtain regulatory approval for
ZYNLONTA® in foreign jurisdictions, and the timing and amount of
future revenue and payments to us from such partnerships; the
impact, if any, from data reported by the University of Miami for
their IIT in FL; the timing and results of the Company’s or its
partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602
as well as the Company’s early-stage pipeline research projects,
actions by the FDA or foreign regulatory authorities with respect
to the Company’s products or product candidates; projected revenue
and expenses; the Company’s indebtedness, including Healthcare
Royalty Management and Oaktree and Blue Owl facilities, and the
restrictions imposed on the Company’s activities by such
indebtedness, the ability to repay such indebtedness and the
significant cash required to service such indebtedness; and the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the “Risk Factors”
section of the Company's Annual Report on Form 20-F and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document. The Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of this press release, except as required by
law.
CONTACTS:
Investors and MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024